Success Metrics

Active Trials
2(33%)

Phase Distribution

Ph phase_2
5
83%
Ph phase_3
1
17%

Phase Distribution

0

Early Stage

5

Mid Stage

1

Late Stage

Phase Distribution6 total trials
Phase 2Efficacy & side effects
5(83.3%)
Phase 3Large-scale testing
1(16.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

6

all time

Status Distribution
Active(4)
Other(2)

Detailed Status

Not yet recruiting2
unknown2
Recruiting2

Development Timeline

Analytics

Development Status

Total Trials
6
Active
2
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 25 (83.3%)
Phase 31 (16.7%)

Trials by Status

not_yet_recruiting233%
unknown233%
recruiting233%

Recent Activity

2 active trials
Showing 5 of 6
not_yet_recruitingphase_2

Oncolytic Virus H101 Combined With Lenvatinib Plus Toripalimab Compared With FOLFOX in Patients With Advanced Biliary Tract Cancer (OPTIONS-06)

NCT06919848
not_yet_recruitingphase_2

Toripalimab Adjuvant Therapy in Subjects With Resected Esophageal Squamous Cell Carcinoma Who Achieved Pathological Complete Response (pCR)

NCT06903871
recruitingphase_2

SABR Combined with Axitinib and Toripalimab in Recurrent or Metastatic RCC

NCT06889649
recruitingphase_2

Radiotherapy Followed by Chemotherapy Combined With Toripalimab in Local Advanced HR-positive,HER2-negative BC.

NCT06705127
unknownphase_2

Toripalimab or Placebo as Adjuvant Therapy in Hepatocellular Carcinoma After Radical Resection

NCT03859128
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT06919848Phase 2

Oncolytic Virus H101 Combined With Lenvatinib Plus Toripalimab Compared With FOLFOX in Patients With Advanced Biliary Tract Cancer (OPTIONS-06)

Not Yet Recruiting
NCT06903871Phase 2

Toripalimab Adjuvant Therapy in Subjects With Resected Esophageal Squamous Cell Carcinoma Who Achieved Pathological Complete Response (pCR)

Not Yet Recruiting
NCT06889649Phase 2

SABR Combined with Axitinib and Toripalimab in Recurrent or Metastatic RCC

Recruiting
NCT06705127Phase 2

Radiotherapy Followed by Chemotherapy Combined With Toripalimab in Local Advanced HR-positive,HER2-negative BC.

Recruiting
NCT03859128Phase 2

Toripalimab or Placebo as Adjuvant Therapy in Hepatocellular Carcinoma After Radical Resection

Unknown
NCT03924050Phase 3

Toripalimab Plus Pemetrexed+Platinus in Advanced Non-small-cell Lungcancer Patients Previsouly Treated EGFR-TKI

Unknown

All 6 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
6